CIPLA:NSE:NSE-Cipla Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1419.75

Change

+17.95 (+1.28)%

Market Cap

USD 1,191.84B

Volume

2.19M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-1.15 (-0.02%)

USD 1,513.85B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+48.45 (+1.65%)

USD 1,023.22B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+6.25 (+0.56%)

USD 970.36B
MANKIND:NSE Mankind Pharma Ltd

+4.05 (+0.18%)

USD 960.38B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+15.80 (+1.81%)

USD 890.87B
LUPIN:NSE Lupin Limited

+56.90 (+2.91%)

USD 868.96B
AUROPHARMA:NSE Aurobindo Pharma Limited

+41.25 (+3.92%)

USD 639.93B
ABBOTINDIA:NSE Abbott India Limited

-91.80 (-0.29%)

USD 633.57B
ALKEM:NSE Alkem Laboratories Limited

+81.85 (+1.77%)

USD 593.38B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+53.75 (+4.03%)

USD 373.94B

ETFs Containing CIPLA:NSE

MEE:CA 0.00 % 0.62 %

N/A

N/A
GLIN VanEck India Growth Leade.. 0.00 % 0.00 %

+1.36 (+3.46%)

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.15% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.15% 83% B 84% B
Trailing 12 Months  
Capital Gain -4.41% 44% F 57% F
Dividend Return 0.88% 65% D 61% D-
Total Return -3.53% 44% F 57% F
Trailing 5 Years  
Capital Gain 226.83% 62% D 57% F
Dividend Return 7.48% 68% D+ 44% F
Total Return 234.31% 63% D 56% F
Average Annual (5 Year Horizon)  
Capital Gain 20.02% 38% F 32% F
Dividend Return 20.62% 40% F 32% F
Total Return 0.61% 60% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 27.65% 84% B 79% B-
Risk Adjusted Return 74.58% 72% C 59% D-
Market Capitalization 1,191.84B 99% N/A 97% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.